Source MS Society:
"Note - While these results are disappointing, they do not affect the proven effectiveness of Gilenya in relapsing remitting MS."
Novartis - the pharmaceutical company that manufacture Gilenya - carried out a global phase 3 clinical trial involving 940 people with primary progressive MS, known as INFORMS. The trial aimed to evaluate the effect of Gilenya (in the form of a once daily tablet) on delaying the progression of disability compared to a dummy drug.
Novartis have announced that results from this trial indicate that Gilenya is not an effective treatment for primary progressive MS. The full results will be presented at an upcoming scientific conference. Read on.